Welcome to our dedicated page for Catalyst Pharmaceuticals news (Ticker: CPRX), a resource for investors and traders seeking the latest updates and insights on Catalyst Pharmaceuticals stock.
Catalyst Pharmaceuticals reports developments as a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing medicines for rare and difficult-to-treat diseases. Its recurring updates center on the commercial performance of FIRDAPSE® (amifampridine), AGAMREE® (vamorolone), and FYCOMPA® (perampanel), along with financial results, revenue guidance, conference presentations, and business updates.
Company news also covers product-specific medical and legal developments, including vamorolone research in Duchenne muscular dystrophy and patent litigation settlements involving FIRDAPSE. Additional announcements address patient advocacy initiatives, support services, and strategic portfolio activity tied to Catalyst’s U.S.-based rare-disease commercial model.
Catalyst Pharmaceuticals (NASDAQ:CPRX) announced a new $200 million share repurchase program effective from October 1, 2025, to December 31, 2026. The company plans to fund the buyback using its existing cash reserves.
As of June 30, 2025, Catalyst maintains a strong financial position with over $650 million in cash and cash equivalents and no funded debt. The repurchases may be executed through open market or privately negotiated purchases, with timing and volume depending on various market factors. The company maintains flexibility to suspend or terminate the program at any time.
Catalyst Pharmaceuticals (Nasdaq: CPRX), a commercial-stage biopharmaceutical company specializing in rare and difficult-to-treat diseases, has announced its participation in four upcoming investor conferences in September 2025.
The company's management team, led by CEO Richard J. Daly, will present at the Wells Fargo Healthcare Conference (Sept. 3), Cantor Global Healthcare Conference (Sept. 4), H.C. Wainwright Global Investment Conference (Sept. 8), and Baird Global Conference (Sept. 9). All presentations will be available via webcast on the company's website with replays accessible for 30 days.
Catalyst Pharmaceuticals (NASDAQ:CPRX) has reached a settlement agreement with Lupin Pharmaceuticals regarding patent litigation for FIRDAPSE® (amifampridine). Under the agreement, Lupin will not market its generic version of FIRDAPSE until February 25, 2035, pending FDA approval.
The settlement resolves the litigation initiated by Catalyst and SERB S.A. in response to Lupin's Abbreviated New Drug Application (ANDA). All ongoing patent litigation between the parties in the U.S. District Court for the District of New Jersey will be terminated. This follows similar settlements with Teva Pharmaceuticals and Inventia Healthcare Limited, while litigation against Hetero remains ongoing.
Catalyst Pharmaceuticals (NASDAQ:CPRX) has announced a settlement agreement with Lupin Pharmaceuticals regarding patent litigation for FIRDAPSE® (amifampridine). Under the agreement, Lupin receives a license to market a generic version of FIRDAPSE starting February 25, 2035, pending FDA approval.
The settlement resolves the patent litigation initiated by Catalyst and SERB S.A. in response to Lupin's Abbreviated New Drug Application (ANDA). All ongoing patent litigation between the parties in the U.S. District Court for the District of New Jersey will be terminated. This follows similar settlements with Teva Pharmaceuticals and Inventia Life Science, while litigation against Hetero remains ongoing.
Catalyst Pharmaceuticals (NASDAQ:CPRX) reported strong Q2 2025 financial results, with total revenues reaching $146.6 million, up 19.4% year-over-year. The company's portfolio showed broad growth, led by FIRDAPSE® ($84.8M, +9.7% YoY), AGAMREE® ($27.4M, +212.9% YoY), and FYCOMPA® ($34.3M).
First half 2025 revenues totaled $288.0 million, a 30.2% increase over 2024. The company maintains its full-year 2025 revenue guidance of $545-565 million. Q2 GAAP net income was $52.1 million ($0.41 per diluted share), up 27.7% YoY. Catalyst ended Q2 with a strong cash position of $652.8 million and no funded debt.
Catalyst Pharmaceuticals (NASDAQ:CPRX) announced that the National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines for Small Cell Lung Cancer (SCLC) to include important recommendations for Lambert Eaton Myasthenic Syndrome (LEMS).
The updated guidelines now include testing for PQ- and N-type voltage-gated calcium channel (VGCC) antibodies and recommend neurological evaluation for diagnosis. Additionally, amifampridine (FIRDAPSE®) is now recommended as a potential treatment option in consultation with neurology.
Notably, approximately 50% of LEMS cases are associated with underlying malignancy, primarily SCLC, with LEMS observed in 3% of SCLC patients. Internal analysis suggests that 90% of LEMS patients with SCLC may be undiagnosed, highlighting a significant unmet medical need.
Catalyst Pharmaceuticals (Nasdaq: CPRX) has appointed Daniel Curran, MD to its Board of Directors. Dr. Curran brings over 25 years of pharmaceutical industry experience, currently serving as Managing Partner of Mountainfield Venture Partners and CEO of Timberlyne Therapeutics.
Dr. Curran's extensive background includes a significant tenure at Takeda Pharmaceutical Company (2008-2023), where he last served as Senior Vice President and Head of Rare Genetics and Hematology Therapeutic Area Unit. His expertise spans strategy, business development, and rare disease therapeutics, making him well-positioned to support Catalyst's growth strategy in rare disease treatments.
Catalyst Pharmaceuticals (NASDAQ: CPRX), a commercial-stage biopharmaceutical company specializing in rare and difficult-to-treat diseases, has scheduled its second quarter 2025 financial results release for August 6, 2025 after market close.
The company will host a conference call and webcast the following day, Thursday, August 7, 2025, at 8:30 AM ET to discuss financial results and provide a business update. Investors can access the call via US/Canada dial-in (877) 407-8912 or international dial-in (201) 689-8059. The webcast will be available on the Investors section of Catalyst's website with a replay accessible for at least 30 days.